Menu
Search
|

Menu

Close
X

Cascadian Therapeutics Inc CASC.OQ (NASDAQ Stock Exchange Global Select Market)

9.99 USD
+0.00 (+0.00%)
As of Feb 17
chart
Previous Close 9.99
Open 10.00
Volume 191,201
3m Avg Volume 135,284
Today’s High 10.00
Today’s Low 9.97
52 Week High 10.20
52 Week Low 3.20
Shares Outstanding (mil) 50.55
Market Capitalization (mil) 221.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.876
FY16
-3.367
FY15
-2.018
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.57
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-40.76
14.43
Return on Equity (TTM)
vs sector
-42.52
16.13

EXECUTIVE LEADERSHIP

Christopher Henney
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Scott Myers
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Julia Eastland
Chief Financial Officer, Vice President - Corporate Development, Secretary, Since 2010
Salary: $300,000.00
Bonus: $68,250.00
Gary Christianson
Chief Operating Officer, Since 2007
Salary: $319,300.00
Bonus: $68,171.00
Scott Peterson
Chief Scientific Officer, Since 2012
Salary: $315,000.00
Bonus: $75,521.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3101 Western Ave Ste 600
SEATTLE   WA   98121-3047

Phone: +1206.8012100

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

SPONSORED STORIES